RESUMO
BACKGROUND Dendritic cells (DCs) specific intercellular adhesion molecule (ICAM)-3-grabbing non integrin receptor (DC-SIGN) binds to subgenera Leishmania promastigotes mediating its interaction with DC and neutrophils, potentially influencing the infection outcome. OBJECTIVES In this work, we investigated whether DC-SIGN receptor is expressed in cells from cutaneous leishmaniasis (CL) lesions as well as the in vitro binding pattern of Leishmania (Viannia) braziliensis (Lb) and L. (L.) amazonensis (La) promastigotes. METHODS DC-SIGN receptor was labeled by immunohistochemistry in cryopreserved CL tissue fragments. In vitro binding assay with CFSE-labeled Lb or La promastigotes and RAJI-transfecting cells expressing DC-SIGN (DC-SIGNPOS) or mock-transfected (DC-SIGNNEG) were monitored by flow cytometry at 2 h, 24 h and 48 h in co-culture. RESULTS In CL lesion infiltrate, DC-SIGNPOS cells were present in the dermis and near the epidermis. Both Lb and La bind to DC-SIGNPOS cells, while binding to DC-SIGNNEG was low. La showed precocious and higher affinity to DC-SIGNhi population than to DC-SIGNlow, while Lb binding was similar in these populations. CONCLUSION Our results demonstrate that DC-SIGN receptor is present in L. braziliensis CL lesions and interact with Lb promastigotes. Moreover, the differences in the binding pattern to Lb and La suggest DC-SIGN can influence in a difference way the intake of the parasites at the first hours after Leishmania infection. These results raise the hypothesis that DC-SIGN receptor could participate in the immunopathogenesis of American tegumentary leishmaniasis accounting for the differences in the outcome of the Leishmania spp. infection.
RESUMO
Leishmania (Viannia) braziliensis is one of the main etiological agents of tegumentary leishmaniasis in Latin America. The establishment of a successful infection in host cells requires several key events including phagocytosis, phagolysosomal maturation impairment, and parasite replication. Autophagy is accountable for the physiological turnover of cellular organelles, degradation of macromolecular structures, and pathogen elimination. In many cases, autophagy control leads to a successful infection, both impairing pathogen elimination or providing nutrients. Here, we have investigated the relationship between autophagy and L. braziliensis infection. We observed that BECLIN1 expression was upregulated early on infection in both in vitro macrophage cultures and biopsies of cutaneous lesions from L. braziliensis infected patients. On the other hand, LC3B expression was downregulated in cutaneous lesions biopsies. A transient pattern of LC3+ cells was observed along L. braziliensis infection, but the number of LC3 puncta did not vary. Additionally, autophagy induction, with rapamycin treatment or through starvation, reduced infection. As expected, rapamycin increased the percentage of LC3+ cells and the number of puncta, but the presence of parasite restricted this effect, indicating LC3-associated autophagy impairment by L. braziliensis. Finally, silencing LC3B but not BECLIN1 promoted infection, confirming BECLIN1 independent and LC3B-related control by the parasite. Taken together, these data indicate macrophage autophagic machinery manipulation by L. braziliensis, resulting in successful establishment and survival into the host cell.
Assuntos
Autofagia , Leishmania braziliensis/fisiologia , Leishmaniose Cutânea/imunologia , Macrófagos/citologia , Macrófagos/parasitologia , Animais , Proteína Beclina-1/metabolismo , Feminino , Humanos , Leishmaniose Cutânea/metabolismo , Macrófagos/imunologia , Proteínas Associadas aos Microtúbulos/metabolismo , FagocitoseRESUMO
Abstract We report the case of a 32-year-old man from Rio de Janeiro, who was infected in the Amazon region of Brazil by Leishmania (Viannia) naiffi. Generally, patients with L. naiffi cutaneous leishmaniasis exhibit a good therapeutic response to either pentavalent antimonials or pentamidine. However, after pentamidine treatment, this patient's infection evolved to therapeutic failure. To understand this clinical outcome, we investigated the presence of the Leishmania RNA virus (LRV) in parasites isolated from the cutaneous lesion; herein, we discuss the possible association between a poor response to pentamidine therapy and the presence of the LRV.
Assuntos
Humanos , Masculino , Adulto , Pentamidina/uso terapêutico , Vírus de RNA/genética , Tripanossomicidas/uso terapêutico , Leishmaniose Cutânea/tratamento farmacológico , Leishmania/virologia , Pentamidina/efeitos adversos , Tripanossomicidas/efeitos adversos , Reação em Cadeia da Polimerase , Falha de TratamentoRESUMO
BACKGROUND: Leishmania (Viannia) braziliensis is the main etiological agent of tegumentary leishmaniasis in the Americas. Parasite molecular diversity and host immune status contribute to extensive variations in its clinical presentation within endemic areas of Brazil. Pentavalent antimonials have been used for more than 60 years as the first-line drug for all cases, despite the potential for severe side effects and refractoriness. In Rio de Janeiro, Brazil, most L. (V.) braziliensis infections are benign with a scarcity of parasites, although metastasis and refractory infections can arise. In this scenario, the use of novel molecular tools can be useful for diagnosis and to assess tissue parasitism, and is of benefit to clinical and therapeutic management. METHODS: In this study, parasite load was assessed by real-time PCR based on the leishmanial small subunit ribosomal RNA gene. RESULTS AND CONCLUSION: The data revealed a tendency to higher tissue parasitism in the skin compared to mucous lesion sites and a reduction with disease progression. Parasite load was lower in poor compared to good responders to antimonials, and was also reduced in recurrent lesions compared to primary ones. However, parasite load became higher with sequential relapses, pointing to an immune system inability to control the infection. Therefore the parasite burden does not seem to be a good predictor of disease progression.
Assuntos
Leishmania braziliensis/isolamento & purificação , Leishmaniose Cutânea/etiologia , Carga Parasitária , Animais , Células Cultivadas , Progressão da Doença , Humanos , Leishmaniose Cutânea/parasitologia , Reação em Cadeia da Polimerase em Tempo RealRESUMO
Leishmania RNA virus (LRV) has been shown to be a symbiotic component of Leishmania parasites in South America. Nested retro-transcription polymerase chain reaction was employed to investigate LRV1 presence in leishmaniasis lesions from Brazil. In endemic areas of Rio de Janeiro (RJ), no LRV1 infection was observed even with mucosal involvement. LRV1 was only detected in Leishmania (V.) guyanensis cutaneous lesions from the northern region, which were obtained from patients presenting with disease reactivation after clinical cure of their primary lesions. Our results indicated that the severity of leishmaniasis in some areas of RJ, where Leishmania (V.) brazi-liensis is the primary etiological agent, was not associated with Leishmania LRV1 infection.
Assuntos
Feminino , Humanos , Leishmania braziliensis/virologia , Leishmaniose Cutânea/parasitologia , Vírus de RNA/genética , Brasil , Reação em Cadeia da Polimerase , Vírus de RNA/classificação , RNA Viral/genética , Índice de Gravidade de DoençaRESUMO
In this study, PCR assays targeting different Leishmania heat-shock protein 70 gene (hsp70) regions, producing fragments ranging in size from 230-390 bp were developed and evaluated to determine their potential as a tool for the specific molecular diagnosis of cutaneous leishmaniasis (CL). A total of 70 Leishmania strains were analysed, including seven reference strains (RS) and 63 previously typed strains. Analysis of the RS indicated a specific region of 234 bp in the hsp70 gene as a valid target that was highly sensitive for detection of Leishmania species DNA with capacity of distinguishing all analyzed species, after polymerase chain reaction-restriction fragment length polymorfism (PCR-RFLP). This PCR assay was compared with other PCR targets used for the molecular diagnosis of leishmaniasis: hsp70 (1400-bp region), internal transcribed spacer (ITS)1 and glucose-6-phosphate dehydrogenase (G6pd). A good agreement among the methods was observed concerning the Leishmania species identification. Moreover, to evaluate the potential for molecular diagnosis, we compared the PCR targets hsp70-234 bp, ITS1, G6pd and mkDNA using a panel of 99 DNA samples from tissue fragments collected from patients with confirmed CL. Both PCR-hsp70-234 bp and PCR-ITS1 detected Leishmania DNA in more than 70% of the samples. However, using hsp70-234 bp PCR-RFLP, identification of all of the Leishmania species associated with CL in Brazil can be achieved employing a simpler and cheaper electrophoresis protocol.
Assuntos
Humanos , DNA de Protozoário/genética , /genética , Leishmania/genética , Leishmaniose Cutânea/diagnóstico , Reação em Cadeia da Polimerase/métodos , Leishmania/isolamento & purificação , Leishmaniose Cutânea/parasitologia , Polimorfismo de Fragmento de Restrição , Sensibilidade e EspecificidadeRESUMO
Infection of humans with Leishmania braziliensis typically results in localized cutaneous leishmaniasis (LCL). Rarely, after months or years of apparent clinical cure, some patients develop the destructive mucosal leishmaniasis (ML). ML results from L. braziliensis dissemination, probably via phagocytic cells. As the preferred cells for Leishmania spp. colonization, macrophages are critical to infection control, and may contribute to parasite dissemination. However, the host factors that determine this outcome are unknown. Matrix metalloproteinase 9 (MMP-9) is known to be important for immune cell migration, macrophage recruitment, and effective granuloma formation. Moreover, MMP-9 has been involved in Mycobacterium tuberculosis dissemination. Here, we demonstrate that in vitro infection of human macrophages with L. braziliensis increased the secretion and activation of MMP-9. We also demonstrate that macrophages from healthy cured individuals with previous history of ML had increased MMP-9 activity compared to LCL cured individuals. These findings may represent a fundamental difference in host innate immunity that could contribute to the clinical leishmaniasis presentation.
Assuntos
Leishmania braziliensis/imunologia , Leishmania braziliensis/patogenicidade , Leishmaniose Mucocutânea/patologia , Macrófagos/parasitologia , Metaloproteinase 9 da Matriz/metabolismo , Adolescente , Adulto , Idoso , Animais , Humanos , Leishmaniose Mucocutânea/imunologia , Leishmaniose Mucocutânea/parasitologia , Macrófagos/enzimologia , Pessoa de Meia-Idade , Adulto JovemRESUMO
Subclinical or asymptomatic infection is documented in individuals living in endemic areas for leishmaniasis suggesting that the development of an appropriate immune response can control parasite replication and maintain tissue integrity. A low morbidity indicates that intrinsic factors could favor resistance to Leishmania infection. Herein, leishmanial T-cell responses induced in subjects with low susceptibility to leishmaniasis as asymptomatic subjects were compared to those observed in cured cutaneous leishmaniasis (CCL) patients, who controlled the disease after antimonial therapy. All of them have shown maintenance of specific long-term immune responses characterized by expansion of higher proportions of CD4+ as compared to CD8+ Leishmania reactive T-lymphocytes. Asymptomatic subjects had lower indexes of in vitro Leishmania induced lymphoproliferative responses and interferon-gamma (IFN-gamma) production in comparison to CCL patients. On the other hand, interleukin (IL-10) production was much higher in asymptomatics than in CCL, while no differences in IL-5 levels were found. In conclusion, long lived T-cell responses achieved by asymptomatic individuals differed from those who had developed symptomatic leishmaniasis in terms of intensity of lymphocyte activation (proliferation or IFN-gamma) and regulatory mechanisms (IL-10). The absence of the disease in asymptomatics could be explained by their intrinsic ability to create a balance between immunoregulatory (IL-10) and effector cytokines (IFN-gamma), leading to parasite destruction without producing skin tissue damage. The establishment of profiles of cell-mediated immune responses associated with resistance against Leishmania infection is likely to make new inroads into understanding the long-lived immune protection against the disease.
Assuntos
Antígenos de Protozoários/imunologia , Leishmania braziliensis/imunologia , Leishmaniose Cutânea/imunologia , Ativação Linfocitária/imunologia , Linfócitos T/imunologia , Animais , Antimônio/uso terapêutico , Antiprotozoários/uso terapêutico , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Células Cultivadas , Citocinas/imunologia , Doenças Endêmicas , Feminino , Humanos , Leishmaniose Cutânea/tratamento farmacológico , Masculino , Compostos Organometálicos/uso terapêuticoRESUMO
Subclinical or asymptomatic infection is documented in individuals living in endemic areas for leishmaniasis suggesting that the development of an appropriate immune response can control parasite replication and maintain tissue integrity. A low morbidity indicates that intrinsic factors could favor resistance to Leishmania infection. Herein, leishmanial T-cell responses induced in subjects with low susceptibility to leishmaniasis as asymptomatic subjects were compared to those observed in cured cutaneous leishmaniasis (CCL) patients, who controlled the disease after antimonial therapy. All of them have shown maintenance of specific long-term immune responses characterized by expansion of higher proportions of CD4+ as compared to CD8+ Leishmania reactive T-lymphocytes. Asymptomatic subjects had lower indexes of in vitro Leishmania induced lymphoproliferative responses and interferon-gamma (IFN-gamma) production in comparison to CCL patients. On the other hand, interleukin (IL-10) production was much higher in asymptomatics than in CCL, while no differences in IL-5 levels were found. In conclusion, long lived T-cell responses achieved by asymptomatic individuals differed from those who had developed symptomatic leishmaniasis in terms of intensity of lymphocyte activation (proliferation or IFN-gamma) and regulatory mechanisms (IL-10). The absence of the disease in asymptomatics could be explained by their intrinsic ability to create a balance between immunoregulatory (IL-10) and effector cytokines (IFN-gamma), leading to parasite destruction without producing skin tissue damage. The establishment of profiles of cell-mediated immune responses associated with resistance against Leishmania infection is likely to make new inroads into understanding the long-lived immune protection against the disease.
Assuntos
Animais , Feminino , Humanos , Masculino , Antígenos de Protozoários/imunologia , Leishmania braziliensis/imunologia , Leishmaniose Cutânea/imunologia , Ativação Linfocitária/imunologia , Linfócitos T/imunologia , Antimônio/uso terapêutico , Antiprotozoários/uso terapêutico , /imunologia , /imunologia , Células Cultivadas , Citocinas/imunologia , Doenças Endêmicas , Leishmaniose Cutânea/tratamento farmacológico , Compostos Organometálicos/uso terapêuticoRESUMO
We report a case of cutaneous mucormycosis in a healthy, immunocompetent young girl (age 14 years). The patient had a 5-year history of a slowly enlarging, erythematous plaque with slight elevated, scaling, circinate borders on the right thigh. Histopathology showed a granulomatous infiltrate with broad, pale, non-septate hyphae. Mycological study identified Mucor hiemalis (Wehmer).
Assuntos
Imunocompetência , Mucor/isolamento & purificação , Mucormicose/diagnóstico , Mucormicose/patologia , Adolescente , Feminino , Humanos , Mucor/classificação , Mucormicose/etiologia , Coxa da PernaRESUMO
Despite more than half a century of use in leishmaniasis, antimony therapy still presents serious problems concerning dosage and toxicity. Low and high doses have been shown to be equally effective. In this paper, the feasibility of injecting one ampoule of meglumine antimoniate intramuscularly every other day until clinical cure is demonstrated, while studying a series of 40 cutaneous leishmaniasis cases. Total dose used varied from 1,822.5 to 12,150mg of pentavalent antimony and total time of treatment varied from 3 to 10 weeks, with 86 percent efficacy. Thirty-six out of the 40 patients are still on follow-up with a mean time of 10.7 ± 7 months and a median of 9 months. No relapse or mucosal lesions have been noted so far. The schedule showed good tolerance and easy application and its efficacy was comparable to the officially recommended WHO schedule. Therefore, such a schedule represents a valuable alternative for the cases with high toxicicity to antimony or daily injections are an obstacle to the treatment.
Apesar de utilizado há mais de meio século no tratamento da leishmaniose, o antimônio apresenta ainda problemas quanto a sua toxicidade e dose ideal. Doses baixas têm se mostrado tão eficazes quanto doses altas. Neste trabalho, apresentamos o resultado do emprego de uma ampola de antimoniato de meglumina intramuscular, em dias alternados, até a cura clínica, numa série de 40 casos. A dose total utilizada, por paciente, variou de 1.822,5 a 12.150mg de antimônio pentavalente e o tempo de tratamento de 3 a 10 semanas com eficácia de 86 por cento. Dos 40 pacientes estudados, 36 ainda estão em acompanhamento, com um tempo médio de 10,7 ± 7 meses e média de 9 meses. Não houve recidivas nem lesões mucosas. O esquema utilizado foi bem tolerado, de fácil aplicação, eficácia comparável ao esquema oficialmente preconizado pela OMS, mostrando-se como valiosa alternativa para os casos com potencial toxicidade ao antimônio ou cuja aplicação de injeções diárias represente um obstáculo ao tratamento.
Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Antiprotozoários/administração & dosagem , Leishmaniose Cutânea/tratamento farmacológico , Meglumina , Meglumina/administração & dosagem , Compostos Organometálicos/administração & dosagem , Antiprotozoários/efeitos adversos , Relação Dose-Resposta a Droga , Esquema de Medicação , Seguimentos , Injeções Intramusculares , Meglumina/efeitos adversos , Compostos Organometálicos/efeitos adversos , Fatores de Tempo , Resultado do TratamentoRESUMO
Two mucocutaneous leishmaniasis cases resistant to therapy are reported here. After the failure of initial therapies (antimony, amphotericin B and/or pentamidine) patients received a low-dose schedule: one ampoule of meglumine antimoniate (405mg of pentavalent antimony [Sb v]) by intramuscular injection, three times a week until complete healing of the lesions. One patient was cured with a total of 30 ampoules in 10 weeks and the other received 36 ampoules in 12 weeks. Both remain clinically cured after one year of follow-up.
São relatados dois casos de leishmaniose mucocutânea resistentes ao tratamento. Depois das terapêuticas iniciais (antimônio, anfotericina B e/ou pentamidina), os pacientes receberam um esquema alternativo: uma ampola de antimoniato de meglumina (405mg de antimônio pentavalnte [Sb v]) por via intramuscular, três vezes por semana até a cura completa das lesões. Um paciente recebeu um total de 30 ampolas durante 10 semanas e o outro, 36 ampolas durante 12 semanas. Ambos permanecem clinicamente curados até um ano após o tratamento.
Assuntos
Humanos , Masculino , Adulto , Pessoa de Meia-Idade , Antiprotozoários/administração & dosagem , Leishmaniose Cutânea/tratamento farmacológico , Meglumina/administração & dosagem , Compostos Organometálicos/administração & dosagem , Esquema de Medicação , Seguimentos , Injeções Intramusculares , Resultado do TratamentoRESUMO
Assim como a natureza, esculturas de civilizações antigas como a Olmeca, podem fornecer elementos comparáveis às lesões. Infelizmente, estas civilizações são pouco conhecidas e admiradas
Assuntos
Síndrome de Melkersson-RosenthalRESUMO
Response to treatment with antimonial drugs varies considerably depending on the parasite strain involved, immune status of the patient and clinical form of the disease. Therapeutic regimens with this first line drug have been frequently modified both, in dose and duration of therapy. A regimen of 20 mg/kg/day of pentavalent antimony (Sb5+) during four weeks without an upper limit on the daily dose is currently recommended for mucosal disease ("espundia"). Side-effects with this dose are more marked in elderly patients, more commonly affected by this form of leishmaniasis. According to our experience, leishmaniasis in Rio de Janeiro responds well to antimony and, in cutaneous disease, high cure rates are obtained with 5 mg/kg/day of Sb5+ during 30 to 45-days. In this study a high rate of cure (91.4 percent) employing this dose was achieved in 36 patients with mild disease in this same geographic region. Side-effects were reduced and no antimony refractoriness was noted with subsequent use of larger dose in patients that failed to respond to initial schedule
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Antiprotozoários/uso terapêutico , Leishmaniose Mucocutânea/tratamento farmacológico , Meglumina/uso terapêutico , Antiprotozoários/administração & dosagem , Seguimentos , Meglumina/administração & dosagem , Reação em Cadeia da Polimerase , Índice de Gravidade de Doença , Fatores de TempoRESUMO
São apresentados dois casos de lesões lupóides, uma rara forma de apresentação clínica da leishmaniose tegumentar no Novo Mundo. Leishmaniose lupóide (LL) é de relato freqüente no Velho Mundo, mas a maioria dos autores emprega essa designação para casos de leishmaniasis recidiva cutis (LRC), originalmente descrita por Berlin. Neste trabalho, os autores salientam as diferenças existentes entre essas duas entidades: a LL como forma de apresentação clínica inicial da doença, e a LRC como o resultado da persistência de parasitas após a cura de uma lesão incial, geralmente ulcerosa. O valor da reação em cadeia de polimerase (PCR) para o diagnóstico parasitológico de lesões pobres em parasitas, caso das lesões lupóides, é enfatizado
Assuntos
Humanos , Masculino , Feminino , Adulto , Leishmaniose Cutânea , Reação em Cadeia da PolimeraseRESUMO
São relatados dois casos de leishmanioses - forma visceral e forma mucosa - em paciente de 52 anos do sexo masculino e em paciente do sexo feminino de 67 anos, respectivamente. Ambos apresentavam história pregressa de hanseníase. Após a confirmação diagnóstica, foram submetidos a tratamento com antimoniato de meglumina na dose de 20 mg (Caso n.1) e 10 mg de Sb5+/Kg de peso por dia (Caso n.2). Os pacientes evoluíram com mal-estar, astenia e anorexia a partir do sexto e décimo dia de tratamento e elevação de 7 a 22 vezes dos níveis séricos de amilase para cada caso, respectivamente. O caso n.2 apresentou também dor abdominal, náusea, hipotensão, febre, aumento de uréia, cretinina e transaminases, cardiotoxicidade e prurido cutâneo. O tratamento foi interrompido nos dois casos com regressão da sintomatologia e retorno gradual dos níveis séricos de amilase aos valores normais, apesar da reintrodução do tratamento no Caso n.1. Não foi possível reintroduzir o tratamento no caso n.2 devido à associação com outros efeitos adversos e demora na normalização da amilasemia. Ambos evoluíram para cura clínica da leishmaniose. Os autores discutem relatos semelhantes encontrados na literatura e sugerem o monitoramento da função pancreática ao lado dos outros parâmetros de controle da toxicidade do antimônio
Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Antimônio , Leishmaniose , PancreatiteRESUMO
Paquidermoperiostose é uma síndrome caracterizada por baqueteamento dos dedos, neoformaçao perióstea em extremidades de ossos longos, além de espessamento, enrugamento e oleosidade da pele da face e couro cabeludo. Os autores descrevem um novo caso e abordam aspecto históricos, clínicos e histopatológicos da moléstia.
Assuntos
Humanos , Masculino , Adulto , Osteoartropatia Hipertrófica Primária/etiologia , Diagnóstico Diferencial , Osteoartropatia Hipertrófica Primária/patologiaRESUMO
Epidermal changes from 32 cutaneous and 3 mucosal American leishmaniasis (ACL) active lesions were studied for HLA-DR, -DP expression, Lanerhans cells and lymphocyte infiltration. In addition to a DR and DQ positivity at the surface of the cells of the inflammatory infiltrate, a strong reaction for DR antigens was detected on keratinocytes. Hyperplasia of Langerhans cells was present in al cutaneous lesions and epidermis was infiltrated by T lymphocytes. When healed lesions of 14 of these subjects were re-biopsied 1 to 12 months after the end of pentavalent antimonial therapy, MHC class antigens could no longer be seen on keratinocytes. Our data represrn evidence for hhe reversibility of the abnormal HLA-DR expression by keratinocytes in ACL after Glucantime therapy or spontaneous scar formation, demonstrating that this expresion is restricted to the period of active lesions. The present findings can be regarded as an indirect evidence that keratinocytes may be involved in the immunopathology of ACL